Acadia Pharmaceuticals Inc. rose 3.27% in premarket trading. The company's stock price increase may be attributed to the positive earnings report from Teva Pharmaceutical Industries Limited, which reported a net income of USD 282 million for the second quarter of 2025, compared to a net loss of USD 846 million a year ago.
Comments
No comments yet